2 - White House News in Chinese (weebly.com)
Pfizer Inc. (/ˈfaɪzər/)[3] is an American multinational pharmaceutical corporation. Pfizer is one of the world's largest pharmaceutical companies, and was ranked 64th on the 2020 Fortune 500 list of the largest U.S. corporations by total revenue, at $47.644 billion as of December 31, 2020.[4][5][1]
Headquartered in Manhattan, Pfizer develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, endocrinology, and neurology. Its products include the blockbuster drug Lipitor (atorvastatin), used to lower LDL blood cholesterol; Lyrica (pregabalin) for neuropathic pain and fibromyalgia; Diflucan (fluconazole), an oral antifungal medication; Zithromax (azithromycin), an antibiotic; Viagra (sildenafil) for erectile dysfunction; Celebrex (also Celebra, celecoxib), an anti-inflammatory drug; and Prevnar 13, a pneumococcal conjugate vaccine...
..."In May 2020, Pfizer began testing four different COVID-19 vaccine variations. It planned to expand human trials to thousands of test patients by September 2020. The pharma company injected doses of the potential vaccine BNT162b2, which was developed by the German biotechnology company BioNTech, and into the first human participants in the U.S. in early May. Based on the results, Pfizer said they "will be able to deliver millions of doses in the October time frame" and expects to produce hundreds of millions of doses in 2021.[83]"... quoted from Wikipedia
Headquartered in Manhattan, Pfizer develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, endocrinology, and neurology. Its products include the blockbuster drug Lipitor (atorvastatin), used to lower LDL blood cholesterol; Lyrica (pregabalin) for neuropathic pain and fibromyalgia; Diflucan (fluconazole), an oral antifungal medication; Zithromax (azithromycin), an antibiotic; Viagra (sildenafil) for erectile dysfunction; Celebrex (also Celebra, celecoxib), an anti-inflammatory drug; and Prevnar 13, a pneumococcal conjugate vaccine...
..."In May 2020, Pfizer began testing four different COVID-19 vaccine variations. It planned to expand human trials to thousands of test patients by September 2020. The pharma company injected doses of the potential vaccine BNT162b2, which was developed by the German biotechnology company BioNTech, and into the first human participants in the U.S. in early May. Based on the results, Pfizer said they "will be able to deliver millions of doses in the October time frame" and expects to produce hundreds of millions of doses in 2021.[83]"... quoted from Wikipedia
Pfizer’s vaccine works well after one dose, and doesn’t always need ultracold storage.
Two positive developments this week could potentially expand access to the Pfizer-BioNTech Covid-19 vaccine at a time when nations around the world are trying to ramp up vaccinations.
A study in Israel showed that the vaccine is robustly effective after the first shot, echoing what other research has shown for the AstraZeneca vaccine and raising the possibility that regulators in some countries could authorize delaying a second dose instead of giving both on the strict schedule of three weeks apart as tested in clinical trials.
Although regulators in the United States have held fast to the requirement that people receive two doses of the Pfizer-BioNTech vaccine three weeks apart, the British government decided to prioritize giving as many people as possible an initial dose, allowing delays of up to 12 weeks before the second dose. The Israeli study could bolster arguments for emulating that approach in other countries.
Published in The Lancet on Thursday and drawing from a group of 9,100 Israeli health care workers, the study showed that Pfizer’s vaccine was 85 percent effective 15 to 28 days after receiving the first dose. Pfizer and BioNTech’s late-stage clinical trials, which enrolled 44,000 people, showed that the vaccine was 95 percent effective if two doses were given three weeks apart.
Dr. Anthony S. Fauci, the nation’s leading expert on infectious diseases and an adviser to President Biden, said at a White House news conference on the pandemic on Friday that the results of the study are not significant enough to change the U.S. recommendations.
He pointed out that the people in the study were on the younger and healthier side and the researchers could not say how long the protection from one shot of the vaccine would last. He also said it was possible that a less-than-optimal dose might not kill the most powerful variants of the virus, theoretically allowing them to spread more quickly in the population.
“We want the public not to be confused. The recommendation from the F.D.A. is two doses, just as it always has been,” Andy Slavitt, a White House virus adviser, said during the briefing. more details
A dose of Pfizer-BioNTech vaccine was drawn into a syringe at the Community Center in Rohnert Park, Calif.
The vaccines are quite safe, and side effects are rare, the C.D.C. reports.
Feb. 20 - The two coronavirus vaccines authorized for use in the United States are reassuringly safe, the Centers for Disease Control and Prevention reported on Friday.
As of Thursday, some 41 million Americans have received at least one dose of a Covid-19 vaccine; about 16.2 million people have been fully vaccinated. But some people remain wary, concerned that the vaccines may have been rushed to market or that side effects may have gone unnoticed.
The new data provide ample evidence that the vaccines are safe, although adverse reactions have occurred in a few patients.
The C.D.C. gathered reports from a long established national surveillance network and a new safety monitoring system, called V-Safe, created specifically to track the coronavirus vaccines. Participants volunteer to enroll and fill out daily surveys reporting symptoms.
The surveillance is neither uniform nor complete, but the tracking effort nonetheless is “the most intense and comprehensive in U.S. history,” the agency said. more details
The vaccines are quite safe, and side effects are rare, the C.D.C. reports.
Feb. 20 - The two coronavirus vaccines authorized for use in the United States are reassuringly safe, the Centers for Disease Control and Prevention reported on Friday.
As of Thursday, some 41 million Americans have received at least one dose of a Covid-19 vaccine; about 16.2 million people have been fully vaccinated. But some people remain wary, concerned that the vaccines may have been rushed to market or that side effects may have gone unnoticed.
The new data provide ample evidence that the vaccines are safe, although adverse reactions have occurred in a few patients.
The C.D.C. gathered reports from a long established national surveillance network and a new safety monitoring system, called V-Safe, created specifically to track the coronavirus vaccines. Participants volunteer to enroll and fill out daily surveys reporting symptoms.
The surveillance is neither uniform nor complete, but the tracking effort nonetheless is “the most intense and comprehensive in U.S. history,” the agency said. more details
Israel says it’s on track to vaccinate everyone over 16 by the end of March. To understand how the small country has vaccinated more of its population than any other so quickly, WSJ visited clinics that are giving shots to young and middle-aged citizens.
Some Covid-19 Vaccines Are Effective After One Dose, Can Be Stored in Normal Freezers, Data Show
In a win for global vaccination goals, BioNTech-Pfizer vaccine is shown to generate strong response with one dose and to maintain potency in standard freezers for two weeks
Feb. 20 - Efforts to vaccinate the world’s population against Covid-19 got a boost Friday after research showed that some vaccines provide strong, one-dose protection, and that one of the vaccines can now be stored in normal freezers instead of ultra-cold ones.
The vaccine developed by Pfizer Inc. and BioNTech SE generates robust immunity after one dose, according to new research out of Israel, and further data showed that the University of Oxford and AstraZeneca PLC vaccine similarly prevented Covid-19 when doses were spaced three months apart.
The findings could boost arguments in favor of delaying the second dose of the two-shot vaccine, as the U.K. has done. They could also have substantial implications on vaccine policy and distribution around the world, simplifying the logistics of distribution.
Pfizer and BioNTech said they have asked U.S. regulators to allow their vaccine to be stored and transported at temperatures consistent with standard freezing, around minus 20 Celsius, following successful internal stability testing. Similar filings were being prepared in other countries.
Should Pfizer’s request be granted by regulators, it would mean its vaccine would vastly expand access in rural regions around the world, as well as pharmacies and physician offices, according to industry experts and officials. source
Some Covid-19 Vaccines Are Effective After One Dose, Can Be Stored in Normal Freezers, Data Show
In a win for global vaccination goals, BioNTech-Pfizer vaccine is shown to generate strong response with one dose and to maintain potency in standard freezers for two weeks
Feb. 20 - Efforts to vaccinate the world’s population against Covid-19 got a boost Friday after research showed that some vaccines provide strong, one-dose protection, and that one of the vaccines can now be stored in normal freezers instead of ultra-cold ones.
The vaccine developed by Pfizer Inc. and BioNTech SE generates robust immunity after one dose, according to new research out of Israel, and further data showed that the University of Oxford and AstraZeneca PLC vaccine similarly prevented Covid-19 when doses were spaced three months apart.
The findings could boost arguments in favor of delaying the second dose of the two-shot vaccine, as the U.K. has done. They could also have substantial implications on vaccine policy and distribution around the world, simplifying the logistics of distribution.
Pfizer and BioNTech said they have asked U.S. regulators to allow their vaccine to be stored and transported at temperatures consistent with standard freezing, around minus 20 Celsius, following successful internal stability testing. Similar filings were being prepared in other countries.
Should Pfizer’s request be granted by regulators, it would mean its vaccine would vastly expand access in rural regions around the world, as well as pharmacies and physician offices, according to industry experts and officials. source
FEBRUARY 19, 2021
Defense Secretary Austin Holds News Conference
Defense Secretary Lloyd Austin held a briefing at the Pentagon where he talked about recent meetings with NATO allies. They discussed common challenges including climate change, terrorism threats, and policies toward China, Russia, Iraq, and Afghanistan. He also said officials within the Defense Department are addressing sexual assault and domestic extremism within military ranks.
Defense Secretary Austin Holds News Conference
Defense Secretary Lloyd Austin held a briefing at the Pentagon where he talked about recent meetings with NATO allies. They discussed common challenges including climate change, terrorism threats, and policies toward China, Russia, Iraq, and Afghanistan. He also said officials within the Defense Department are addressing sexual assault and domestic extremism within military ranks.
China and the US likely to dance diplomatically without crossing each other's redlines
Feb. 20 - ..."As Yang noted, China's position has been stable and consistent, while Biden acknowledged the U.S. has been the opposite. This is why although Yang said more, little of it was new; and while Biden said less, much of it described changes.
Although a soft reset arguably is in everyone's best interests, neither side realistically expects relations to warm considerably overnight. Both realize relations are tense and even fraught on some fronts. Both indicate a willingness to cooperate. Politically, Biden cannot afford to move too quickly on relations with China given more pressing matters at home, which above all require broad political support from Democrats and Republicans, with committed China hawks found in both parties. Beijing understands that patience might be required, as the White House press secretary indicated it would be a day after Biden's speech, and will certainly embrace it as long as sovereignty isn't compromised.
The key for both sides will be to build from positives without crossing each other's redlines. In fact, neither side nor the world at large can afford increasing conflict, and both China and Biden's team know how to dance diplomatically. It's not unreasonable to be optimistic". quoted from
Feb. 20 - ..."As Yang noted, China's position has been stable and consistent, while Biden acknowledged the U.S. has been the opposite. This is why although Yang said more, little of it was new; and while Biden said less, much of it described changes.
Although a soft reset arguably is in everyone's best interests, neither side realistically expects relations to warm considerably overnight. Both realize relations are tense and even fraught on some fronts. Both indicate a willingness to cooperate. Politically, Biden cannot afford to move too quickly on relations with China given more pressing matters at home, which above all require broad political support from Democrats and Republicans, with committed China hawks found in both parties. Beijing understands that patience might be required, as the White House press secretary indicated it would be a day after Biden's speech, and will certainly embrace it as long as sovereignty isn't compromised.
The key for both sides will be to build from positives without crossing each other's redlines. In fact, neither side nor the world at large can afford increasing conflict, and both China and Biden's team know how to dance diplomatically. It's not unreasonable to be optimistic". quoted from
No comments:
Post a Comment